HRP20100610T1 - Nova fsh glikozilacijska varijanta d3n - Google Patents
Nova fsh glikozilacijska varijanta d3n Download PDFInfo
- Publication number
- HRP20100610T1 HRP20100610T1 HR20100610T HRP20100610T HRP20100610T1 HR P20100610 T1 HRP20100610 T1 HR P20100610T1 HR 20100610 T HR20100610 T HR 20100610T HR P20100610 T HRP20100610 T HR P20100610T HR P20100610 T1 HRP20100610 T1 HR P20100610T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- acid sequence
- nucleic acid
- vector
- Prior art date
Links
- 230000013595 glycosylation Effects 0.000 title 1
- 238000006206 glycosylation reaction Methods 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 239000013598 vector Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000001279 glycosylating effect Effects 0.000 claims 1
- 208000021267 infertility disease Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Pregnancy & Childbirth (AREA)
- Physics & Mathematics (AREA)
- Gynecology & Obstetrics (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Mutirani FSH, naznačen time da se ?-podjedinica sastoji od SEQ ID NO: 3 i pri čemu se α-podjedinica sastoji od SEQ ID NO: 4. Patent sadrži još 14 patentnih zahtjeva.
Claims (15)
1. Mutirani FSH, naznačen time da se β-podjedinica sastoji od SEQ ID NO: 3 i pri čemu se α-podjedinica sastoji od SEQ ID NO: 4.
2. Mutirani FSH prema zahtjevu 1, naznačen time da je bilo koji od 0 do 6 asparaginskih ostataka glikoziliran.
3. Mutirani FSH prema zahtjevu 1, naznačen time da je ostatak N3 α-podjedinice glikoziliran.
4. Vektor naznačen time da sadrži nukleinsku kiselinu koja enkodira aminokiselinsku sekvencu SEQ ID NO: 3 i nukleinsku kiselinu koja enkodira aminokiselinsku sekvencu SEQ ID NO: 4.
5. Vektor prema zahtjevu 4, naznačen time da je vektor ekspresijski vektor.
6. Stanica domaćin, naznačena time da sadrži vektor prema zahtjevu 4.
7. Stanica domaćin prema zahtjevu 6, naznačena time da stanica je stanica sisavca.
8. Postupak dobivanja mutiranog FSH prema zahtjevu 1, naznačen time da sadrži:
(a) dobivanje stanice koja sadrži prvu nukleinsku kiselinu koja enkodira amino kiselinsku sekvencu SEQ ID NO: 3 i drugu nukleinsku kiselinu koja enkodira amino kiselinsku sekvencu SEQ ID NO: 4
(b) kultiviranje stanice pod uvjetima koji omogućavaju ekspresiju prve i druge nukleinske kiseline
9. Postupak prema zahtjevu 8, naznačen time da je stanica sposobna glikozilirati protein.
10. Postupak prema zahtjevu 9, naznačen time da stanica sadrži jedan vektor koji sadrži nukleinsku kiselinu koja enkodira amino kiselinsku sekvencu SEQ ID NO: 3 i nukleinsku kiselinu koja enkodira amino kiselinsku sekvencu SEQ ID NO: 4.
11. Postupak prema zahtjevu 9, naznačen time da stanica sadrži:
(a) prvi vektor koji sadrži nukleinsku kiselinu koja enkodira amino kiselinsku sekvencu SEQ ID NO: 3 i drugu nukleinsku kiselinu koja enkodira amino kiselinsku sekvencu SEQ ID NO: 4
(b) drugi vektor koji sadrži nukleinsku kiselinu koja enkodira amino kiselinsku sekvencu SEQ ID NO: 4.
12. Farmaceutski pripravak naznačen time da sadrži mutirani FSH prema zahtjevu 1 i opcijski farmaceutski prihvatljiv nosač ili ekcipijent.
13. Farmaceutski pripravak prema zahtjevu 12, naznačen time da je za liječenje neplodnih sisavaca.
14. Farmaceutski pripravak prema zahtjevu 12, naznačen time da je za poticanje folikulogeneze kod sisavaca.
15. Farmaceutski pripravak prema zahtjevu 12, naznačen time da je za izazivanje hiperstimulacije jajnika kod sisavaca.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75948606P | 2006-01-17 | 2006-01-17 | |
| PCT/US2007/001004 WO2007084441A2 (en) | 2006-01-17 | 2007-01-16 | Novel fsh glycosylation variant d3n |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100610T1 true HRP20100610T1 (hr) | 2010-12-31 |
Family
ID=38163618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100610T HRP20100610T1 (hr) | 2006-01-17 | 2010-11-11 | Nova fsh glikozilacijska varijanta d3n |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7956034B2 (hr) |
| EP (1) | EP1981908B1 (hr) |
| JP (1) | JP2009523445A (hr) |
| KR (1) | KR20080094697A (hr) |
| CN (1) | CN101370825B (hr) |
| AR (1) | AR059054A1 (hr) |
| AT (1) | ATE487738T1 (hr) |
| AU (1) | AU2007207697B2 (hr) |
| BR (1) | BRPI0706628A2 (hr) |
| CA (1) | CA2633844A1 (hr) |
| CY (1) | CY1110953T1 (hr) |
| DE (1) | DE602007010425D1 (hr) |
| DK (1) | DK1981908T3 (hr) |
| EA (1) | EA013974B1 (hr) |
| HR (1) | HRP20100610T1 (hr) |
| IL (1) | IL192547A (hr) |
| PL (1) | PL1981908T3 (hr) |
| PT (1) | PT1981908E (hr) |
| RS (1) | RS51792B (hr) |
| SI (1) | SI1981908T1 (hr) |
| WO (1) | WO2007084441A2 (hr) |
| ZA (1) | ZA200805194B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007022799A1 (en) | 2005-08-26 | 2007-03-01 | Ares Trading S.A. | Process for the preparation of glycosylated interferon beta |
| WO2007065918A2 (en) | 2005-12-09 | 2007-06-14 | Ares Trading S.A. | Method for purifying fsh or a fsh mutant |
| ZA200804677B (en) | 2005-12-22 | 2009-10-28 | Serono Lab | FSH Mutants |
| WO2009053360A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying an fc-containing protein |
| US20100249381A1 (en) * | 2007-10-22 | 2010-09-30 | David Delvaille | Method for Purifying FC-Fusion Proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100404551C (zh) * | 1997-06-25 | 2008-07-23 | 雪兰诺实验室有限公司 | 二硫键交联的糖蛋白激素类似物及其制备和应用 |
| AU2001231531A1 (en) | 2000-02-11 | 2001-08-20 | Maxygen Aps | Follicle stimulating hormones |
| JP4310275B2 (ja) * | 2001-10-22 | 2009-08-05 | アプライド リサーチ システムズ アース ホールディング エヌ．ヴィ． | 変異体糖タンパク質 |
| UA88879C2 (en) * | 2003-09-02 | 2009-12-10 | Эплайд Рисерч Системз Эрс Холдинг Н.В. | Fsh glycosylation mutant |
| WO2007065918A2 (en) * | 2005-12-09 | 2007-06-14 | Ares Trading S.A. | Method for purifying fsh or a fsh mutant |
-
2007
- 2007-01-16 DK DK07716617.1T patent/DK1981908T3/da active
- 2007-01-16 PL PL07716617T patent/PL1981908T3/pl unknown
- 2007-01-16 CN CN2007800030734A patent/CN101370825B/zh not_active Expired - Fee Related
- 2007-01-16 AU AU2007207697A patent/AU2007207697B2/en not_active Ceased
- 2007-01-16 EA EA200870177A patent/EA013974B1/ru not_active IP Right Cessation
- 2007-01-16 JP JP2008551305A patent/JP2009523445A/ja active Pending
- 2007-01-16 BR BRPI0706628-7A patent/BRPI0706628A2/pt not_active IP Right Cessation
- 2007-01-16 WO PCT/US2007/001004 patent/WO2007084441A2/en active Application Filing
- 2007-01-16 CA CA002633844A patent/CA2633844A1/en not_active Abandoned
- 2007-01-16 PT PT07716617T patent/PT1981908E/pt unknown
- 2007-01-16 EP EP07716617A patent/EP1981908B1/en active Active
- 2007-01-16 AT AT07716617T patent/ATE487738T1/de active
- 2007-01-16 KR KR1020087020053A patent/KR20080094697A/ko not_active Application Discontinuation
- 2007-01-16 DE DE602007010425T patent/DE602007010425D1/de active Active
- 2007-01-16 US US12/158,539 patent/US7956034B2/en not_active Expired - Fee Related
- 2007-01-16 RS RS20100568A patent/RS51792B/en unknown
- 2007-01-16 ZA ZA200805194A patent/ZA200805194B/xx unknown
- 2007-01-16 SI SI200730438T patent/SI1981908T1/sl unknown
- 2007-01-17 AR ARP070100200A patent/AR059054A1/es not_active Application Discontinuation
-
2008
- 2008-06-30 IL IL192547A patent/IL192547A/en not_active IP Right Cessation
-
2010
- 2010-11-11 HR HR20100610T patent/HRP20100610T1/hr unknown
- 2010-11-25 CY CY20101101080T patent/CY1110953T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL192547A (en) | 2012-04-30 |
| EA013974B1 (ru) | 2010-08-30 |
| DK1981908T3 (da) | 2010-12-13 |
| AU2007207697B2 (en) | 2012-01-19 |
| EP1981908A2 (en) | 2008-10-22 |
| PL1981908T3 (pl) | 2011-04-29 |
| WO2007084441A2 (en) | 2007-07-26 |
| IL192547A0 (en) | 2009-02-11 |
| JP2009523445A (ja) | 2009-06-25 |
| PT1981908E (pt) | 2010-11-23 |
| AU2007207697A1 (en) | 2007-07-26 |
| BRPI0706628A2 (pt) | 2011-04-05 |
| RS51792B (en) | 2011-12-31 |
| CN101370825B (zh) | 2012-10-10 |
| US20080280832A1 (en) | 2008-11-13 |
| ZA200805194B (en) | 2009-10-28 |
| WO2007084441A3 (en) | 2007-09-07 |
| DE602007010425D1 (de) | 2010-12-23 |
| EP1981908B1 (en) | 2010-11-10 |
| CN101370825A (zh) | 2009-02-18 |
| KR20080094697A (ko) | 2008-10-23 |
| ATE487738T1 (de) | 2010-11-15 |
| SI1981908T1 (sl) | 2011-01-31 |
| CA2633844A1 (en) | 2007-07-26 |
| CY1110953T1 (el) | 2015-06-11 |
| AR059054A1 (es) | 2008-03-12 |
| US7956034B2 (en) | 2011-06-07 |
| EA200870177A1 (ru) | 2009-02-27 |
| AU2007207697A2 (en) | 2008-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100610T1 (hr) | Nova fsh glikozilacijska varijanta d3n | |
| HRP20201185T1 (hr) | Gdf zamke | |
| ES2585280T3 (es) | Asparaginasa de basidiomicetos | |
| AR049177A1 (es) | Polipeptidos y conjugados de interferon-alfa | |
| BRPI0606612A2 (pt) | expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto | |
| PE20230409A1 (es) | Composiciones alimenticias con alto contenido en proteinas | |
| IL179617A0 (en) | Method of stabilizing proteins | |
| RU2010108308A (ru) | Способ получения гетерогенных белков | |
| HRP20110430T1 (hr) | Fsh glikozilacijski mutant | |
| NZ514951A (en) | Recombinant protein production in a cultured human cell | |
| RU2010147076A (ru) | Аналоги инсулина специфичные к изоформам | |
| NZ570553A (en) | Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines | |
| MX362028B (es) | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. | |
| BRPI0516176A (pt) | polipeptìdeo, dna, microorganismo, e, processo para produzir l-arginina, l-ornitina ou l-citrulina | |
| CO6270336A2 (es) | Composiciones pepticidas que comprenden uno o mas polipetidos | |
| WO2009004054A3 (en) | A cxc chemokine receptor 4 (cxcr4) antagonistic polypeptide | |
| AR070716A1 (es) | Metodos para modificar el punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en la region de determinacion de la complementariedad (cdr) | |
| BRPI0815578B8 (pt) | peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina | |
| AR040293A1 (es) | Produccion de peptidos y proteinas por acumulacion de cuerpos proteicos derivados de reticulo endoplasmico en plantas | |
| RU2010120677A (ru) | Клетка для получения гетеропротеинов и способ получения на ее основе | |
| CA2400908A1 (en) | Fusion protein having enhanced in vivo erythropoietin activity | |
| ECSP066495A (es) | Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv) | |
| ATE449790T1 (de) | Rekombinante gelatinepartikel für die zelladhäsion | |
| NZ594481A (en) | Truncated cystine-knot proteins | |
| ATE386054T1 (de) | Glycosylierte humane interferon alpha isoform |